Genomic surveillance, characterisation and intervention of a carbapenem-resistant Acinetobacter baumannii outbreak in critical care

Competing Interest Statement

PNAH has received research grants from MSD, Sandoz and Shionogi Ltd, outside of the submitted work, and speaker fees from Pfizer paid to The University of Queensland. DLP reports receiving grants and personal fees from Shionogi and Merck Sharp and Dohme and personal fees from Pfizer, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate. JL has received personal fees from Pfizer and MSD and grants from MSD paid to The University of Queensland. The other authors have no conflicts of interest to declare.

Funding Statement

LWR was supported by an Australian Government Research Training Program (RTP) Scholarship. SAB, PNAH and MAS were supported by fellowships from the Australian National Health and Medical Research Council (GNT1090456, GNT1157530 and GNT1106930, respectively). The work was supported by VC Strategic Intitiative Funding from The University of Queensland (2016-2018) and grants from the Queensland Genomics Health Alliance (now Queensland Genomics), Queensland Health, Queensland Government. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was provided by the RBWH HREC as a low-risk study with waiver of consent (HREC/16/QRBW/581).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes